ATE191922T1 - Feststellung der wechselwirkungsstelle zwischen p21-waf und pcna und deren therapeutischen verwendungen - Google Patents

Feststellung der wechselwirkungsstelle zwischen p21-waf und pcna und deren therapeutischen verwendungen

Info

Publication number
ATE191922T1
ATE191922T1 AT95936023T AT95936023T ATE191922T1 AT E191922 T1 ATE191922 T1 AT E191922T1 AT 95936023 T AT95936023 T AT 95936023T AT 95936023 T AT95936023 T AT 95936023T AT E191922 T1 ATE191922 T1 AT E191922T1
Authority
AT
Austria
Prior art keywords
pcna
binding
substances
waf
determination
Prior art date
Application number
AT95936023T
Other languages
English (en)
Inventor
David Philip Lane
Lynne Suzanne Cox
Emma Warbrick
David Moore Glover
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Application granted granted Critical
Publication of ATE191922T1 publication Critical patent/ATE191922T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT95936023T 1994-11-03 1995-11-03 Feststellung der wechselwirkungsstelle zwischen p21-waf und pcna und deren therapeutischen verwendungen ATE191922T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9422175A GB9422175D0 (en) 1994-11-03 1994-11-03 Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
PCT/GB1995/002583 WO1996014334A1 (en) 1994-11-03 1995-11-03 IDENTIFICATION OF THE p21WAF1-PCNA INTERACTION SITE AND THERAPEUTIC APPLICATIONS THEREOF

Publications (1)

Publication Number Publication Date
ATE191922T1 true ATE191922T1 (de) 2000-05-15

Family

ID=10763826

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95936023T ATE191922T1 (de) 1994-11-03 1995-11-03 Feststellung der wechselwirkungsstelle zwischen p21-waf und pcna und deren therapeutischen verwendungen

Country Status (8)

Country Link
US (1) US6242201B1 (de)
EP (1) EP0789711B1 (de)
JP (1) JPH10509312A (de)
AT (1) ATE191922T1 (de)
CA (1) CA2203909A1 (de)
DE (1) DE69516416T2 (de)
GB (1) GB9422175D0 (de)
WO (1) WO1996014334A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233943T3 (es) * 1994-05-24 2005-06-16 Baylor College Of Medicine Mimeticos de inhibidores de la sintesis de dna derivados de celulas senescentes.
GB9509557D0 (en) * 1995-05-11 1995-07-05 Univ Dundee PCNA binding substance
DE69736351D1 (de) 1996-05-08 2006-08-31 Cyclacel Ltd Methoden und mittel zur hemmung der cdk4-aktivität
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
FR2754822B1 (fr) * 1996-10-18 1998-11-27 Rhone Poulenc Rorer Sa Polypeptides comprenant des domaines de la proteine gax, impliques dans la repression de transcription et/ou interagissant avec d'autres proteines, acides nucleiques correspondants et leurs utilisations
WO1998041873A1 (en) * 1997-03-14 1998-09-24 The University Court Of The University Of Glasgow Methods for identifying cell cycle regulators
US6489305B1 (en) * 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
EP0974649A1 (de) * 1998-06-22 2000-01-26 Universität Zürich Screening-System
DE60006538T2 (de) * 1999-05-21 2004-09-30 Matsushita Electric Industrial Co., Ltd., Kadoma Beschreibbare optische Platte
US7449544B2 (en) 1999-11-30 2008-11-11 Cyclacel Limited p21 peptides
GB9928323D0 (en) * 1999-11-30 2000-01-26 Cyclacel Ltd Peptides
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
US7259232B1 (en) * 2000-10-27 2007-08-21 Nymox Pharmaceutical Corporation Preferred segments of neural thread protein
WO2003016491A2 (en) * 2001-08-15 2003-02-27 The Regents Of The University Of California Retrovirus isolated from mantle histiocytes in mantle cell lymphoma
US20080026992A1 (en) * 2003-10-20 2008-01-31 Ludger Hengst Tyrosine Phosphorylation of Cdk Inhibitor Proteins of the Cip/Kip Family
CN101507822B (zh) 2003-11-24 2012-06-06 坎吉有限公司 皮肤瘢痕形成的减少
GB0410498D0 (en) * 2004-05-11 2004-06-16 Cyclacel Ltd Crystal
US20080125404A1 (en) 2004-08-27 2008-05-29 Cyclacel Limited Purine and Pyrimidine Cdk Inhitbitors and Their use for The Treatment of Autoimmune Diseases
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
WO2011104309A1 (en) * 2010-02-24 2011-09-01 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compounds for the treatment of inflammation and neutropenia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662698A1 (fr) 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
US5302706A (en) 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US5596079A (en) 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
PT665886E (pt) 1992-10-16 2003-10-31 Cold Spring Harbor Lab Rearranjo de complexos de ciclina e suas utilizacoes
EP0723402B1 (de) 1993-08-30 2010-08-18 Baylor College Of Medicine Inhibitoren der dna synthese aus alternden zellen
WO1995013375A1 (en) 1993-11-10 1995-05-18 The Johns Hopkins University Tumor suppressor waf1
ES2233943T3 (es) 1994-05-24 2005-06-16 Baylor College Of Medicine Mimeticos de inhibidores de la sintesis de dna derivados de celulas senescentes.
EP0850066A1 (de) 1995-07-20 1998-07-01 Worcester Foundation For Biomedical Research, Inc. Verfahren zur selektiven abtötung oder hemmung des wachstums von zellen, welche das waf1-gen exprimieren

Also Published As

Publication number Publication date
EP0789711B1 (de) 2000-04-19
JPH10509312A (ja) 1998-09-14
EP0789711A1 (de) 1997-08-20
DE69516416T2 (de) 2000-10-26
AU694574B2 (en) 1998-07-23
AU3811395A (en) 1996-05-31
CA2203909A1 (en) 1996-05-17
GB9422175D0 (en) 1994-12-21
WO1996014334A1 (en) 1996-05-17
US6242201B1 (en) 2001-06-05
DE69516416D1 (de) 2000-05-25

Similar Documents

Publication Publication Date Title
ATE191922T1 (de) Feststellung der wechselwirkungsstelle zwischen p21-waf und pcna und deren therapeutischen verwendungen
RU95115239A (ru) Аналог эритропоэтина
BR0213786A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
EA199801044A1 (ru) Модуляторы регенерации тканей
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
DE69725293D1 (de) N-(2 oxoacetyl oder sulphonyl)-pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
BR9408025A (pt) Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases
CY1111120T1 (el) Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση
DE69534165D1 (de) Adenovirus mit glutathion peroxydate gene
BR0207638A (pt) Métodos de uso de proteìna de filamento neural para tratar tumores e outras condições que requerem a remoção ou destruição de células
BG106051A (en) MUTATIONS OF THE ENDOTHELIUM NITROGEN OXIDE SYNTHETASIS, eNOS AND THIEIR APPLICATION FOR GENE THERAPY AND THRAPEUTIC SCREENING
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
EA200001124A1 (ru) Способ генной терапии
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
ES549115A0 (es) Procedimiento de producir preparaciones para tratar pacien- tes de hemofilia a inhibidores
ATE190318T1 (de) Pcna bindende substanz
SE8901342L (sv) Biologiska material, foerfaranden foer framstaellning av biologiska material samt foer anvaendning av saadana material i terapi
CA2370098A1 (en) Human beta-trcp protein
DE69837265D1 (de) Polypeptide zur regenerierung des nervensystems
EA200401390A1 (ru) N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
ATE300554T1 (de) Bindegewebe-wachstumsfaktor 3.
ATE216707T1 (de) Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises
BR9914466A (pt) "contortrostatina (cn) e métodos para seu uso na prevenção da metástase e outras condições"
BR0013665A (pt) Uso de uma proteìna histacalina, composição farmacêutica, e, método de tratar ou impedir conjuntivite

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties